Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Zydus Cadila

Drug Profile

Coronavirus vaccine - Zydus Cadila

Latest Information Update: 24 Apr 2020

At a glance

  • Originator Zydus Cadila
  • Class Attenuated vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 20 Apr 2020 Preclinical trials in COVID-2019 infections (Prevention) in Europe (Parenteral)
  • 20 Apr 2020 Preclinical trials in COVID-2019 infections (Prevention) in India (Parenteral)
  • 20 Apr 2020 Zydus Cadila plans clinical development in COVID-2019 infections (Prevention) (Parenteral) by second quarter of 2020

Development Overview

Introduction

Coronavirus vaccine is a recombinant, live attenuated, measles virus vectored against COVID-19 is being developed by Zydus Cadila, for the prevention of COVID-2019 infections using Etna Biotech's measles reverse genetics technology. The recombinant measles virus (rMV) produced by reverse genetics would express codon-optimised proteins of the coronavirus and intends to induce long-term specific neutralising antibodies to protect against the infection. Preclinical development is underway in Europe and India.

Zydus Cadila is looking for partners for development of vaccine for COVID-2019 infections (Zydus Cadila website, February 2020).

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Attenuated vaccines, Synthetic vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07 (Vaccines)

  • EPhMRA code

    J7A9 (Other specified single component)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical Europe, India Parenteral / unspecified Zydus Cadila 20 Apr 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Zydus Cadila Originator India
Zydus Cadila Owner India
Etna Biotech Technology Provider Italy

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Zydus Cadila - Unspecified - 24 Feb 2020

Future Events

Expected Date Event Type Description Updated
30 Jun 2020 Trial Update Zydus Cadila plans clinical development in COVID-2019 infections (Prevention) (Parenteral) by second quarter of 2020 [1] 24 Apr 2020

Development History

Event Date Update Type Comment
20 Apr 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in Europe (Parenteral) [1] Updated 24 Apr 2020
20 Apr 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in India (Parenteral) [1] Updated 24 Apr 2020
20 Apr 2020 Trial Update Zydus Cadila plans clinical development in COVID-2019 infections (Prevention) (Parenteral) by second quarter of 2020 [1] Updated 24 Apr 2020
24 Feb 2020 Licensing Status Coronavirus vaccine - Zydus Cadila is available for licensing as of 24 Feb 2020. https://www.zyduscadila.com/ (Zydus Cadila Pipeline, February 2020) Updated 05 Mar 2020
15 Feb 2020 Phase Change Early research in COVID-2019-infections in India, Europe (Prevention) (Parenteral) Updated 05 Mar 2020

References

  1. Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b.

    Media Release
Back to top